About
mPGES-1 inhibition in cardiovascular diseases and cancer.
Areas of Focus
Categories
Small Molecule Pharmaceutical
Team (12)
Charlotte Edenius
Charlotte Edenius
Gesynta Pharma
team_member
Cristina Csimma
Cristina Csimma
Gesynta Pharma
team_member
Daniele Scarinci
Daniele Scarinci
Gesynta Pharma
team_member
David Colpman
David Colpman
Gesynta Pharma
team_member
Eva Johnsson
Eva Johnsson
Gesynta Pharma
team_member
Gunilla Ekström
Gunilla Ekström
Gesynta Pharma
team_member
Clinical Trials (3)
View allTotal Trials
3
As Lead Sponsor
3
As Collaborator
0
Total Enrollment
180
By Phase
PHASE2: 1PHASE1: 2
By Status
COMPLETED: 3
Clinical Trials Pipeline3 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2018
2019
2020
2021
2022
2023
Today
Hover over trial bars to see details
Recent Trials
NCT04744207Lead Sponsor
A Study to Investigate Safety of GS-248 and Efficacy on Raynauds' Phenomenon in Systemic Sclerosis
PHASE2Completed
94 participants
Started: Dec 29, 2020 · Completed: Jun 15, 2022
NCT04617509Lead Sponsor
A Study in Healthy Subjects to Evaluate Pharmacokinetics and Food Effect After Dosing of GS-248
PHASE1Completed
14 participants
Started: Mar 31, 2020 · Completed: May 27, 2020
NCT04036227Lead Sponsor
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GS-248
PHASE1Completed
72 participants
Started: Jul 3, 2019 · Completed: Dec 20, 2019
Locations (1)
Headquarters
Stockholm, Sweden
Map
Loading map...